Physician profile
Michael Yu
NPI 1255993291
$1,505.53
in general payments reported to CMS, 2019-2025
12 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2022: $57.56 · 2023: $598 · 2024: $529 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,303.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $461.23 | 2024-2025 | Krystexxa, Tavneos, Otezla |
| Horizon Therapeutics Plc | $207.68 | 2023 | Krystexxa |
| Kiniksa Pharmaceuticals, Ltd. | $135.00 | 2023 | Arcalyst |
| Pfizer INC. | $127.21 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2023 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $115.72 | 2019 | |
| Merck Sharp & Dohme LLC | $111.39 | 2019-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $87.14 | 2022-2024 | Eliquis |
| Mallinckrodt Hospital Products INC. | $79.06 | 2025 | Acthar |
| Gilead Sciences, INC. | $31.23 | 2023-2024 | Veklury |
| Astrazeneca Pharmaceuticals Lp | $12.98 | 2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.